Literature DB >> 9119379

Characterization of mutations at the mouse phenylalanine hydroxylase locus.

J D McDonald1, C K Charlton.   

Abstract

Two genetic mouse models for human phenylketonuria have been characterized by DNA sequence analysis. For each, a distinct mutation was identified within the protein coding sequence of the phenylalanine hydroxylase gene. This establishes that the mutated locus is the same as that causing human phenylketonuria and allows a comparison between these mouse phenylketonuria models and the human disease. A genotype/phenotype relationship that is strikingly similar to the human disease emerges, underscoring the similarity of phenylketonuria in mouse and man. In PAHENU1, the phenotype is mild. The Pahenu1 mutation predicts a conservative valine to alanine amino acid substitution and is located in exon 3, a gene region where serious mutations are rare in humans. In PAHENU2, the phenotype is severe. The Pahenu2 mutation predicts a radical phenylalanine to serine substitution and is located in exon 7, a gene region where serious mutations are common in humans. In PAHENU2, the sequence information was used to devise a direct genotyping system based on the creation of a new Alw26I restriction endonuclease site.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119379     DOI: 10.1006/geno.1996.4508

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  31 in total

1.  Advances and challenges in phenylketonuria.

Authors:  Cary O Harding; Nenad Blau
Journal:  J Inherit Metab Dis       Date:  2010-12       Impact factor: 4.982

2.  PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.

Authors:  Jennifer E Embury; Catherine E Charron; Anatoly Martynyuk; Andreas G Zori; Bin Liu; Syed F Ali; Neil E Rowland; Philip J Laipis
Journal:  Brain Res       Date:  2006-11-15       Impact factor: 3.252

Review 3.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

4.  Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).

Authors:  Kelly J Hamman; Shelley R Winn; Cary O Harding
Journal:  Mol Genet Metab       Date:  2011-08-04       Impact factor: 4.797

5.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

6.  In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.

Authors:  Gladys Ho; Juergen Reichardt; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2013-03-27       Impact factor: 4.982

7.  Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle.

Authors:  C O Harding; K Wild; D Chang; A Messing; J A Wolff
Journal:  Gene Ther       Date:  1998-05       Impact factor: 5.250

Review 8.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

9.  Tissue-specific activation of mitogen-activated protein kinases for expression of transthyretin by phenylalanine and its metabolite, phenylpyruvic acid.

Authors:  Joo Won Park; Mi Hee Lee; Jin Ok Choi; Hae Young Park; Sung Chul Jung
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

10.  Regionally selective decreases in cerebral glucose metabolism in a mouse model of phenylketonuria.

Authors:  M Qin; C Beebe Smith
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.